JP2014509653A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509653A5
JP2014509653A5 JP2014502821A JP2014502821A JP2014509653A5 JP 2014509653 A5 JP2014509653 A5 JP 2014509653A5 JP 2014502821 A JP2014502821 A JP 2014502821A JP 2014502821 A JP2014502821 A JP 2014502821A JP 2014509653 A5 JP2014509653 A5 JP 2014509653A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
treatment
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014502821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509653A (ja
JP6242331B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031361 external-priority patent/WO2012135571A1/en
Publication of JP2014509653A publication Critical patent/JP2014509653A/ja
Publication of JP2014509653A5 publication Critical patent/JP2014509653A5/ja
Application granted granted Critical
Publication of JP6242331B2 publication Critical patent/JP6242331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014502821A 2011-04-01 2012-03-30 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター Active JP6242331B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US61/470,849 2011-04-01
US201161559489P 2011-11-14 2011-11-14
US61/559,489 2011-11-14
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155625A Division JP6275784B2 (ja) 2011-04-01 2016-08-08 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター

Publications (3)

Publication Number Publication Date
JP2014509653A JP2014509653A (ja) 2014-04-21
JP2014509653A5 true JP2014509653A5 (enExample) 2015-04-09
JP6242331B2 JP6242331B2 (ja) 2017-12-06

Family

ID=46931927

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014502821A Active JP6242331B2 (ja) 2011-04-01 2012-03-30 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
JP2016155625A Active JP6275784B2 (ja) 2011-04-01 2016-08-08 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
JP2018001910A Withdrawn JP2018052987A (ja) 2011-04-01 2018-01-10 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016155625A Active JP6275784B2 (ja) 2011-04-01 2016-08-08 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
JP2018001910A Withdrawn JP2018052987A (ja) 2011-04-01 2018-01-10 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター

Country Status (29)

Country Link
US (7) US8710219B2 (enExample)
EP (2) EP2694075B1 (enExample)
JP (3) JP6242331B2 (enExample)
KR (2) KR101902325B1 (enExample)
CN (2) CN105461736B (enExample)
AU (1) AU2012236367B2 (enExample)
BR (1) BR112013025340B1 (enExample)
CA (1) CA2830822C (enExample)
CL (1) CL2013002823A1 (enExample)
CY (2) CY1117785T1 (enExample)
DK (2) DK2694075T3 (enExample)
EA (1) EA022434B9 (enExample)
ES (2) ES2577982T3 (enExample)
HR (2) HRP20160545T1 (enExample)
HU (2) HUE028910T2 (enExample)
IL (2) IL228588A (enExample)
LT (1) LT3111938T (enExample)
ME (2) ME02451B (enExample)
MX (1) MX340577B (enExample)
PE (1) PE20141382A1 (enExample)
PL (2) PL2694075T3 (enExample)
PT (2) PT2694075T (enExample)
RS (2) RS54903B1 (enExample)
SG (2) SG193563A1 (enExample)
SI (2) SI2694075T1 (enExample)
SM (2) SMT201900435T1 (enExample)
TW (1) TWI571469B (enExample)
WO (1) WO2012135571A1 (enExample)
ZA (2) ZA201307082B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54230B1 (sr) 2009-01-08 2015-12-31 Curis Inc. Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
ME02451B (me) 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
JP6051434B2 (ja) 2011-11-14 2016-12-27 イグニタ、インク. AXLおよびc−METキナーゼ阻害剤としてのウラシル誘導体
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
ES2833473T3 (es) * 2015-04-21 2021-06-15 Chengdu Zenitar Biomedical Tech Co Ltd Derivados de purinil-N-hidroxil pirimidin formamida, método de preparación y uso de los mismos
WO2018015895A1 (en) * 2016-07-19 2018-01-25 National Institute Of Plant Genome Research Novel protein against fungal pathogens
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
US11406647B2 (en) * 2017-11-06 2022-08-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
MX2021002742A (es) 2018-09-11 2021-08-11 Curis Inc Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc.
EP3968215A1 (en) 2020-09-09 2022-03-16 Koninklijke Philips N.V. Determining target object type and position
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP4648628B2 (ja) 2002-03-13 2011-03-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
MY140390A (en) 2002-03-13 2009-12-31 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
PL214756B1 (pl) 2003-01-29 2013-09-30 Takeda Pharmaceutical Zwiazki tienopirymidynowe, kompozycja farmaceutyczna zawierajaca te zwiazki oraz ich zastosowanie
JP4993374B2 (ja) * 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
ES2553178T3 (es) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
CN101370791B (zh) 2006-01-19 2012-05-02 詹森药业有限公司 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物
AU2007206941B2 (en) 2006-01-19 2012-09-13 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2347187T3 (es) 2006-04-26 2010-10-26 F. Hoffmann-La Roche Ag Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k.
CA2650295C (en) * 2006-04-26 2015-12-29 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
BRPI0710943A2 (pt) 2006-04-26 2012-06-26 Genentech Inc compostos farmacêuticos
US20100016435A1 (en) 2006-05-16 2010-01-21 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
KR20090077914A (ko) 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CA2662580C (en) 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8399452B2 (en) 2006-10-28 2013-03-19 Methylgene Inc. Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2007333243B2 (en) 2006-12-07 2013-03-14 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
RU2009134223A (ru) 2007-02-15 2011-03-20 Новартис АГ (CH) Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
US20080234332A1 (en) 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US8247397B2 (en) * 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909631B (zh) * 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
RS54230B1 (sr) * 2009-01-08 2015-12-31 Curis Inc. Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
TWI428336B (zh) 2009-10-12 2014-03-01 Hoffmann La Roche Pi3k抑制劑及mek抑制劑之組合
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療
ME02451B (me) * 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
EP3313443B9 (en) 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗

Similar Documents

Publication Publication Date Title
JP2014509653A5 (enExample)
JP2013522326A5 (enExample)
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2012255026A5 (enExample)
JP2015536964A5 (enExample)
JP2015508103A5 (enExample)
JP2017537066A5 (enExample)
MX2014015158A (es) Derivados de piridinona y piridazinona.
JP2014504256A5 (enExample)
JP2013525444A5 (enExample)
JP2017525730A5 (enExample)
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
JP2013526544A5 (enExample)
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2009242409A5 (enExample)
JP2017514910A5 (enExample)
JP2017519027A5 (enExample)
PH12016501651A1 (en) Triazine compound and use thereof for medical purposes
JP2014518544A5 (enExample)
JP2015509540A5 (enExample)
RU2014117707A (ru) Способ лечения пролиферативного заболевания
JP2014533272A5 (enExample)
JP2018510138A5 (enExample)
JP2015516419A5 (enExample)
WO2013149148A3 (en) Dosage forms of halofuginone and methods of use